## Nancy M Heddle

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7023382/publications.pdf

Version: 2024-02-01

87888 71685 6,217 135 38 76 citations g-index h-index papers 143 143 143 4857 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	Clinical Practice Guidelines From the AABB. JAMA - Journal of the American Medical Association, 2016, 316, 2025.	7.4	871
2	The Role of the Plasma from Platelet Concentrates in Transfusion Reactions. New England Journal of Medicine, 1994, 331, 625-628.	27.0	504
3	The premature infants in need of transfusion (pint) study: A randomized, controlled trial of a restrictive (LOW) versus liberal (HIGH) transfusion threshold for extremely low birth weight infants. Journal of Pediatrics, 2006, 149, 301-307.e3.	1.8	497
4	Effect of Short-Term vs. Long-Term Blood Storage on Mortality after Transfusion. New England Journal of Medicine, 2016, 375, 1937-1945.	27.0	278
5	A randomized controlled trial comparing the frequency of acute reactions to plasma-removed platelets and prestorage WBC-reduced platelets. Transfusion, 2002, 42, 556-566.	1.6	189
6	A prospective study to determine the frequency and clinical significance of alloimmunization postâ $\in$ transfusion. British Journal of Haematology, 1995, 91, 1000-1005.	2.5	159
7	A randomized controlled trial comparing standard- and low-dose strategies for transfusion of platelets (SToP) to patients with thrombocytopenia. Blood, 2009, 113, 1564-1573.	1.4	150
8	A randomized controlled trial comparing plasma removal with white cell reduction to prevent reactions to platelets. Transfusion, 1999, 39, 231-238.	1.6	139
9	Perioperative Management of Dabigatran. Circulation, 2015, 132, 167-173.	1.6	133
10	Pathophysiology of febrile nonhemolytic transfusion reactions. Current Opinion in Hematology, 1999, 6, 420.	2.5	118
11	A pilot randomized trial of adjuvant rituximab or placebo for nonsplenectomized patients with immune thrombocytopenia. Blood, 2012, 119, 1356-1362.	1.4	111
12	The risk of bleeding in thrombocytopenic patients with acute myeloid leukemia. Haematologica, 2006, 91, 1530-7.	<b>3.</b> 5	110
13	The contribution of the haematocrit to thrombocytopenic bleeding in experimental animals. British Journal of Haematology, 1994, 86, 347-350.	2.5	107
14	Effect of Fibrinogen Concentrate vs Cryoprecipitate on Blood Component Transfusion After Cardiac Surgery. JAMA - Journal of the American Medical Association, 2019, 322, 1966.	7.4	106
15	Duration of red cell storage before transfusion and in-hospital mortality. American Heart Journal, 2010, 159, 737-743.e1.	2.7	101
16	Combination of 4Ts score and PF4/H-PaGIA for diagnosis and management of heparin-induced thrombocytopenia: prospective cohort study. Blood, 2015, 126, 597-603.	1.4	101
17	Rituximab plus standard of care for treatment of primary immune thrombocytopenia: a systematic review and meta-analysis. Lancet Haematology,the, 2015, 2, e75-e81.	4.6	99
18	Transfusion of fresher vs older red blood cells in hospitalized patients: a systematic review and meta-analysis. Blood, 2016, 127, 400-410.	1.4	94

#	Article	IF	CITATIONS
19	Methodologic issues in the use of bleeding as an outcome in transfusion medicine studies. Transfusion, 2003, 43, 742-752.	1.6	85
20	Acute Paroxysmal Cold Hemoglobinuria. Transfusion Medicine Reviews, 1989, 3, 219-229.	2.0	82
21	New Strategies for the Optimal Use of Platelet Transfusions. Hematology American Society of Hematology Education Program, 2008, 2008, 198-204.	2.5	82
22	Forecasting Ontario's blood supply and demand. Transfusion, 2012, 52, 366-374.	1.6	74
23	Comparing the efficacy and safety of apheresis and whole blood–derived platelet transfusions: a systematic review. Transfusion, 2008, 48, 1447-1458.	1.6	71
24	Hemostatic efficacy of pathogen-inactivated vs untreated platelets: a randomized controlled trial. Blood, 2018, 132, 223-231.	1.4	71
25	Prophylactic platelet transfusion for prevention of bleeding in patients with haematological disorders after chemotherapy and stem cell transplantation. The Cochrane Library, 2012, , CD004269.	2.8	66
26	Utilization of platelet transfusions in the intensive care unit: indications, transfusion triggers, and platelet count responses. Transfusion, 2006, 46, 1286-1291.	1.6	65
27	Combination immunosuppressant therapy for patients with chronic refractory immune thrombocytopenic purpura. Blood, 2010, 115, 29-31.	1.4	65
28	The effect of blood storage duration on inâ€hospital mortality: a randomized controlled pilot feasibility trial. Transfusion, 2012, 52, 1203-1212.	1.6	61
29	Red blood cell processing methods and in-hospital mortality: a transfusion registry cohort study. Lancet Haematology,the, 2016, 3, e246-e254.	4.6	57
30	Prophylactic platelet transfusion for haemorrhage after chemotherapy and stem cell transplantation., 2004, , CD004269.		53
31	A multicenter pilot-randomized controlled trial of the feasibility of an augmented red blood cell transfusion strategy for patients treated with induction chemotherapy for acute leukemia or stem cell transplantation. Transfusion, 2007, 48, 071003012013009-???.	1.6	53
32	The association between blood donor sex and age and transfusion recipient mortality: an exploratory analysis. Transfusion, 2019, 59, 482-491.	1.6	51
33	The challenges of measuring bleeding outcomes in clinical trials of platelet transfusions. Transfusion, 2013, 53, 1531-1543.	1.6	46
34	A descriptive analysis of international transfusion practice and bleeding outcomes in patients with acute leukemia. Transfusion, 2006, 46, 903-911.	1.6	45
35	A prospective study to determine the safety of omitting the antiglobulin crossmatch from pretransfusion testing. British Journal of Haematology, 1992, 81, 579-584.	2.5	42
36	Platelet transfusions in children: results of a randomized, prospective, crossover trial of plasma removal and a prospective audit of WBC reduction. Transfusion, 2002, 42, 753-758.	1.6	41

3

#	Article	IF	Citations
37	Febrile nonhemolytic transfusion reactions to platelets. Current Opinion in Hematology, 1995, 2, 478-483.	2.5	40
38	In vivo recovery and survival of apheresis and whole blood-derived platelets: a paired comparison in healthy volunteers. Transfusion, 2006, 46, 257-264.	1.6	40
39	Prevention of bedside errors in transfusion medicine (PROBE-TM) study: a cluster-randomized, matched-paired clinical areas trial of a simple intervention to reduce errors in the pretransfusion bedside check. Transfusion, 2007, 47, 771-780.	1.6	39
40	Exploring donor and product factors and their impact on red cell post-transfusion outcomes. Transfusion Medicine Reviews, 2018, 32, 28-35.	2.0	39
41	Platelet Transfusion Practices in the ICU. Chest, 2016, 150, 516-523.	0.8	37
42	Systematic review of rituximab for autoimmune diseases: a potential alternative to intravenous immune globulin. Transfusion, 2018, 58, 2729-2735.	1.6	37
43	Time to rethink clinically important outcomes in platelet transfusion trials. Transfusion, 2011, 51, 430-434.	1.6	36
44	Red blood cell transfusion: 2016 clinical practice guidelines from AABB. Transfusion, 2016, 56, 2627-2630.	1.6	36
45	Red blood cell storage and in-hospital mortality: a secondary analysis of the INFORM randomised controlled trial. Lancet Haematology,the, 2017, 4, e544-e552.	4.6	34
46	The research question. Transfusion, 2007, 47, 15-17.	1.6	33
47	Geographical variations in the correlates of blood donor turnout rates: An investigation of Canadian metropolitan areas. International Journal of Health Geographics, 2009, 8, 56.	2.5	31
48	A new tool to assess bleeding severity in patients with chemotherapyâ€induced thrombocytopenia (CME). Transfusion, 2012, 52, 2466-2474.	1.6	31
49	Sexâ€mismatched red blood cell transfusions and mortality: A systematic review and metaâ€analysis. Vox Sanguinis, 2019, 114, 505-516.	1.5	31
50	Errors in patient specimen collection: application of statistical process control. Transfusion, 2008, 48, 2143-2151.	1.6	30
51	Factors affecting the frequency of red blood cell outdates: an approach to establish benchmarking targets. Transfusion, 2009, 49, 219-226.	1.6	30
52	Individual and contextual determinants of blood donation frequency with a focus on clinic accessibility: A case study of Toronto, Canada. Health and Place, 2012, 18, 424-433.	3.3	27
53	Challenges and opportunities to prevent transfusion errors: a Qualitative Evaluation for Safer Transfusion (QUEST). Transfusion, 2012, 52, 1687-1695.	1.6	27
54	Adjudicating bleeding events in a platelet dose study: impact on outcome results and challenges. Transfusion, 2011, 51, 2304-2310.	1.6	25

#	Article	IF	Citations
55	Exploratory studies on the age of transfused blood and inâ€hospital mortality in patients with cardiovascular diagnoses. Transfusion, 2015, 55, 364-372.	1.6	25
56	Warmâ€reactive (immunoglobulin G) autoantibodies and laboratory testing best practices: review of the literature and survey of current practice. Transfusion, 2017, 57, 463-477.	1.6	25
57	Universal leukoreduction and acute transfusion reactions: putting the puzzle together. Transfusion, 2004, 44, 1-4.	1.6	23
58	Platelet quality measured with dynamic light scattering correlates with transfusion outcome in hematologic malignancies. Transfusion, 2009, 49, 2276-2284.	1.6	23
59	Blood loss from laboratory testing, anemia, and red blood cell transfusion in the intensive care unit: a retrospective study. Transfusion, 2020, 60, 256-261.	1.6	23
60	A study protocol for a randomised controlled trial evaluating clinical effects of platelet transfusion products: the Pathogen Reduction Evaluation and Predictive Analytical Rating Score (PREPAReS) trial. BMJ Open, 2016, 6, e010156.	1.9	22
61	A decision integration strategy for short-term demand forecasting and ordering for red blood cell components. Operations Research for Health Care, 2021, 29, 100290.	1.2	22
62	Convalescent plasma for adults with acute COVID-19 respiratory illness (CONCOR-1): study protocol for an international, multicentre, randomized, open-label trial. Trials, 2021, 22, 323.	1.6	21
63	A systematic assessment of the quality of reporting for platelet transfusion studies. Transfusion, 2010, 50, 2135-2144.	1.6	19
64	Composite outcomes in clinical trials: what are they and when should they be used?. Transfusion, 2011, 51, 11-13.	1.6	17
65	Devices to Reduce the Volume of Blood Taken for Laboratory Testing in ICU Patients: A Systematic Review. Journal of Intensive Care Medicine, 2020, 35, 1074-1079.	2.8	17
66	Perioperative oral eltrombopag versus intravenous immunoglobulin in patients with immune thrombocytopenia: a non-inferiority, multicentre, randomised trial. Lancet Haematology,the, 2020, 7, e640-e648.	4.6	16
67	Benchmarking: Applications to Transfusion Medicine. Transfusion Medicine Reviews, 2012, 26, 321-332.	2.0	15
68	Rationale and Design of the Informing Fresh versus Old Red Cell Management (INFORM) Trial: An International Pragmatic Randomized Trial. Transfusion Medicine Reviews, 2016, 30, 25-29.	2.0	15
69	Paroxysmal cold hemoglobinuria: a difficult diagnosis in adult patients. Transfusion, 2017, 57, 137-143.	1.6	15
70	Protocol for a phase III, non-inferiority, randomised comparison of a new fibrinogen concentrate versus cryoprecipitate for treating acquired hypofibrinogenaemia in bleeding cardiac surgical patients: the FIBRES trial. BMJ Open, 2018, 8, e020741.	1.9	15
71	Clinical trials evaluating pathogenâ€reduced platelet products: methodologic issues and recommendations. Transfusion, 2013, 53, 1843-1855.	1.6	14
72	A 13-Question Approach to Resolving Serological Discrepancies in the Transfusion Medicine Laboratory. Laboratory Medicine, 2014, 45, 193-206.	1.2	14

#	Article	IF	Citations
73	Quantification of Cell-Free DNA in Red Blood Cell Units in Different Whole Blood Processing Methods. Journal of Blood Transfusion, 2016, 2016, 1-5.	3.3	14
74	Not all red cell concentrate units are equivalent: international survey of processing and in vitro quality data. Vox Sanguinis, 2019, 114, 783-794.	1.5	14
75	Systematic reviews of guidelines and studies for single versus multiple unit transfusion strategies. Transfusion, 2018, 58, 2841-2860.	1.6	12
76	The use of antiâ€D to improve postâ€transfusion platelet response: a randomized trial. British Journal of Haematology, 1995, 89, 163-168.	2.5	11
77	The role of comparative effectiveness research in transfusion medicine clinical trials: proceedings of a National Heart, Lung, and Blood Institute workshop. Transfusion, 2012, 52, 1363-1378.	1.6	11
78	Exploring resource allocation and alternate clinic accessibility landscapes for improved blood donor turnout. Applied Geography, 2013, 45, 89-97.	3.7	11
79	Intravenous Immunoglobulin (IVIg) Utilization in Immune Thrombocytopenia (ITP): A Multi-Center, Retrospective Review. Drugs - Real World Outcomes, 2015, 2, 35-42.	1.6	11
80	Transfusion premedication practices among pediatric health care practitioners in Canada: results of a national survey. Transfusion, 2016, 56, 2296-2302.	1.6	11
81	The association between platelet transfusions and mortality in patients with critical illness. Transfusion, 2019, 59, 1962-1970.	1.6	11
82	A crosswalk tabular review on methods and outcomes from randomized clinical trials using pathogen reduced platelets. Transfusion, 2020, 60, 1267-1277.	1.6	10
83	From demand forecasting to inventory ordering decisions for red blood cells through integrating machine learning, statistical modeling, and inventory optimization. Transfusion, 2022, 62, 87-99.	1.6	10
84	Clinical research design and reporting: always room for improvement!. Transfusion, 2007, 47, 2-3.	1.6	8
85	Reviewing manuscripts: tips and responsibilities. Transfusion, 2009, 49, 2265-2268.	1.6	8
86	Effect of a thrombopoietin receptor agonist on use of intravenous immune globulin in patients with immune thrombocytopenia. Transfusion, 2016, 56, 73-79.	1.6	8
87	A study of the agreement between patient self-assessment and study personnel assessment of bleeding symptoms. Transfusion, 2006, 46, 1926-1933.	1.6	7
88	Impact of organizational interventions on reducing inappropriate intravenous immunoglobulin (IVIG) usage: A systematic review and meta-analysis. Transfusion and Apheresis Science, 2018, 57, 215-221.	1.0	7
89	Cost-effectiveness of eltrombopag versus intravenous immunoglobulin for the perioperative management of immune thrombocytopenia. Blood Advances, 2021, , .	5.2	7
90	A policy informing qualitative study to improve the process of blood product recalls and withdrawals. Transfusion, 2008, 48, 2585-2595.	1.6	6

#	Article	IF	Citations
91	Do expert assessments converge? An exploratory case study of evaluating and managing a blood supply risk. BMC Public Health, 2011, 11, 666.	2.9	6
92	An evaluation of overall effectiveness and treatment satisfaction with intravenous immunoglobulin among patients with immune thrombocytopenia. Transfusion, 2016, 56, 1739-1744.	1.6	6
93	Exploring the components of bleeding outcomes in transfusion trials for patients with hematologic malignancy. Transfusion, 2021, 61, 286-293.	1.6	6
94	Exposure To ABO Compatible But Non-Group Identical Blood and In-Hospital Mortality. Blood, 2013, 122, 3651-3651.	1.4	6
95	Evidenceâ€based clinical reporting: a need for improvement. Transfusion, 2002, 42, 1106-1110.	1.6	5
96	A reporting guideline for clinical platelet transfusion studies from the BEST Collaborative. Transfusion, 2013, 53, 1328-1334.	1.6	5
97	A benchmarking program to reduce red blood cell outdating: implementation, evaluation, and a conceptual framework. Transfusion, 2015, 55, 1621-1627.	1.6	5
98	Short-Term versus Long-Term Blood Storage. New England Journal of Medicine, 2017, 376, 1091-1094.	27.0	5
99	Revisiting study design and methodology for pathogen reduced platelet transfusions: a round table discussion. Transfusion, 2020, 60, 1604-1611.	1.6	5
100	CONSORT comes to TRANSFUSION. Transfusion, 2009, 49, 194-195.	1.6	4
101	Prophylactic platelet transfusions. Current Opinion in Hematology, 2014, 21, 521-527.	2.5	4
102	An international investigation into AB plasma administration in hospitals: how many AB plasma units were infused? The HABSWIN study. Transfusion, 2018, 58, 151-157.	1.6	4
103	Peri-Operative Eltrombopag or Immune Globulin for Patients with Immune Thrombocytopaenia (The) Tj ETQq1 1 C	).784314 3.4	rgBT /Overlo
104	Platelet variability index: a measure of platelet count fluctuations in patients with immune thrombocytopenia. Blood Advances, 2021, 5, 4256-4264.	5.2	4
105	Clinical Research Designs: Quantitative Studies. Vox Sanguinis, 2002, 83, 247-250.	1.5	3
106	Risks, benefits and the role of stakeholders in pathogen reduction technology. Health, Risk and Society, 2014, 16, 547-564.	1.7	3
107	CONSORT and clinical trial reporting: room for improvement. Transfusion, 2016, 56, 781-783.	1.6	3
108	Platelet transfusion practice and platelet refractoriness for a cohort of pediatric oncology patients: A singleâ€center study. Pediatric Blood and Cancer, 2020, 67, e28734.	1.5	3

#	Article	IF	Citations
109	Utilising red cell antigen genotyping and serological phenotyping in sickle cell disease patients to riskâ€stratify patients for alloimmunisation risk. Transfusion Medicine, 2020, 30, 263-274.	1.1	3
110	Necrotizing enterocolitis and mortality after transfusion of ABO nonâ€identical blood. Transfusion, 2021, 61, 3094-3103.	1.6	3
111	Databaseâ€driven research and big data analytic approaches in transfusion medicine. Transfusion, 2022, 62, 1427-1434.	1.6	3
112	Critical developments of 2017: a review of the literature from selected topics in transfusion. A committee report from the AABB Clinical Transfusion Medicine Committee. Transfusion, 2018, 58, 1065-1075.	1.6	2
113	Neutropenia and monocytopenia in recurrent anaphylactoid reactions after red blood cell transfusions in a woman with immunoglobulin A (IgA) deficiency and antiâ€IgA. Transfusion, 2018, 58, 2320-2325.	1.6	2
114	Design issues with clinical experimental platelet transfusion studies. Transfusion Alternatives in Transfusion Medicine, $2006$ , $8$ , $106-113$ .	0.2	1
115	Febrile, Allergic, and Other Noninfectious Transfusion Reactions. , 2007, , 677-690.		1
116	Designing laboratory-based research studies: is it time for a change?. Transfusion, 2007, 47, 2336-2337.	1.6	1
117	From cytokines to pragmatic designs: changing paradigms. Transfusion, 2017, 57, 2298-2306.	1.6	1
118	Top 10 mistakes made in research. Transfusion, 2018, 58, 2478-2482.	1.6	1
119	Febrile and Allergic Transfusion Reactions. , 0, , 83-89.		1
120	Genome-Wide Association Study Identifies Variation in <i>ABO</i> As Risk Factor for Platelet Reactivity in Heparin-Induced Thrombocytopenia. Blood, 2020, 136, 38-39.	1.4	1
121	Transfusion-Related Iron Overload: A Covert Risk Of Supportive Cancer Care. Blood, 2013, 122, 3656-3656.	1.4	1
122	Triple Immunosuppressive Therapy in Patients with Chronic Resistant Immune Thrombocytopenic Purpura; a Case Series of 11 Patients Blood, 2004, 104, 2059-2059.	1.4	1
123	Prolonged Blood Storage and Risk of Posttransfusion Acute Kidney Injury. Anesthesiology, 2022, 136, 138-147.	2.5	1
124	The randomized controlled trial: in celebration of TRANSFUSION's 50th. Transfusion, 2010, 50, 1173-1178.	1.6	0
125	Clinical Outcomes and Red Blood Cell Storage. , 2018, , 305-319.		0
126	Pitfalls in Interpreting Platelet Function Tests in Thrombocytopenic Patients Referred by a Hematologist for Diagnostic Testing: Results from a Single Center Prospective Study Blood, 2005, 106, 3982-3982.	1.4	0

#	Article	IF	Citations
127	Understanding Treatment Preferences In Patients with Primary Immune Thrombocytopenia Contemplating Splenectomy: A Qualitative Study. Blood, 2010, 116, 392-392.	1.4	O
128	Use of Intravenous Immune Globulin in Patients with Immune Thrombocytopenia Before and After Romiplostim: Real-World Experience. Blood, 2012, 120, 4641-4641.	1.4	0
129	Are Children with Cancer Receiving Myelosuppressive Therapy At Risk for Transfusion-Related Iron Overload?. Blood, 2012, 120, 1180-1180.	1.4	0
130	Ten-Year Canadian National Prospective Data On Utilization of Anti-Hemophilic Concentrates: Indications and Trends. Blood, 2012, 120, 1186-1186.	1.4	0
131	Transfusion Related Alloimmunization In Children: Epidemiology and Effects Of Chemotherapy (TRACE-EC Study). Blood, 2013, 122, 1161-1161.	1.4	0
132	Perioperative Management Of Patients On Dabigatran – a Prospective Cohort Study. Blood, 2013, 122, 3637-3637.	1.4	0
133	The Use Of Platelet Transfusions In The Intensive Care Unit and Impact On Platelet Count: A 30,000 Patient Registry Study. Blood, 2013, 122, 1154-1154.	1.4	0
134	Platelet quality measured with dynamic light scattering correlates with transfusion outcome in hematologic malignancies. Transfusion, 2009, , no-no.	1.6	0
135	Use of Irradiated Red Blood Cell Transfusions in Newborns to Improve Intracerebral Saturation. JAMA Pediatrics, 2022, , e220149.	6.2	0